Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 2001 Mar;39(3):1148–1151. doi: 10.1128/JCM.39.3.1148-1151.2001

Comparison of Three Nucleic Acid Amplification Assays of Cerebrospinal Fluid for Diagnosis of Cytomegalovirus Encephalitis

Arabella Bestetti 1, Chiara Pierotti 1, Mariarosa Terreni 2, Alessandra Zappa 1, Luca Vago 3, Adriano Lazzarin 1, Paola Cinque 1,*
PMCID: PMC87891  PMID: 11230445

Abstract

The diagnostic reliabilities of three cytomegalovirus (CMV) nucleic acid amplification assays of cerebrospinal fluid (CSF) were compared by using CSF samples from human immunodeficiency virus-infected patients with a postmortem histopathological diagnosis of CMV encephalitis (n = 15) or other central nervous system conditions (n = 16). By using a nested PCR assay, the quantitative COBAS AMPLICOR CMV MONITOR PCR, and the NucliSens CMV pp67 nucleic acid sequence-based amplification assay, sensitivities were 93.3, 86.6, and 93.3%, respectively, and specificities were 93.7, 93.7, and 87.5%, respectively. The COBAS AMPLICOR assay revealed significantly higher CMV DNA levels in patients with diffuse ventriculoencephalitis than in patients with focal periventricular lesions.


Human cytomegalovirus (CMV)-induced complications of the central nervous system (CNS) in patients with human immunodeficiency virus (HIV) infection mainly consist of encephalitis (CMV-E) and polyradiculomyelitis. Histologically, patients with CMV-E can present with ventriculoencephalitis, focal parenchymal lesions, or microglial nodules; in addition, isolated cells containing typical CMV inclusions can also be recognized (1). Although diffuse encephalopathy is the clinical correlate of CMV-E, its clinical presentation may not be specific and a definitive diagnosis requires the identification of the virus in the brain or cerebrospinal fluid (CSF). In this regard, PCR of CSF for the detection of CMV DNA is the most reliable method for the diagnosis of CMV-related CNS lesions in vivo in HIV-infected patients, with most of the studies indicating sensitivity and specificity values of 80 and 100%, respectively (46, 810, 16). The aim of the study described here was to compare the diagnostic reliabilities of two new commercially available assays for the detection of CMV genomes in peripheral blood, the COBAS AMPLICOR HIV Monitor PCR (the COBAS AMPLICOR PCR) and the NucliSens CMV pp67 nucleic acid sequence-based amplification assay (NASBA), with that of an in-house nested PCR test for CSF analysis (4, 5).

(The content of this article was presented at the Neuroscience of HIV Infection 2000, Edinburgh, United Kingdom, 22 to 24 June 2000.)

Patients belonged to a cohort of HIV-infected patients with CNS symptoms admitted to the San Raffaele Hospital, Milan, Italy, between 1992 and 1998. Thirty-one patients with or without CMV encephalitis were selected because of the availability of both postmortem tissues and a CSF sample that had been taken during the 180 days preceding death and that had been stored at −80°C and never previously thawed. Six patients (four with CMV-E and two with other CNS diseases) were included in a previous study (5). Upon admission, the patients underwent a complete neurological and neuroradiological examination and CSF analysis. Additional CSF specimens were drawn as necessary during the subsequent follow-up. All of the patients who died in hospital underwent postmortem examination (5). At autopsy, CMV-E was defined as the presence of inflammatory and/or necrotizing brain lesions, with CMV identified by histology on the basis of typical viral inclusions and confirmed by immunochemistry with a monoclonal mouse anti-CMV antibody (clone CCH2, diluted 1:25; Dakopatts, Glostrup, Denmark).

The nested PCR assay was performed as described previously (4). This test was used to examine the CSF at the time of the diagnostic workup but was repeated for the present study at the same time of the other two assays and using the same stored CSF samples. CSF samples were tested by the COBAS AMPLICOR test with a 200-μl volume and by the manufacturer's recommendation for analysis of plasma (13, 14). For the Organon Teknika NucliSens CMV pp67 NASBA, an initial CSF sample volume of 100 μl was used and the analysis was performed as recommended for analysis of blood (2, 3).

At neuropathological examination, 15 patients had CMV-E and 16 patients had other CNS conditions. All of the patients with CMV-E had ventriculoencephalitis, and 11 also had focal parenchymal lesions. Further details of the postmortem findings are shown in Tables 1 and 2. The analytical sensitivity of the nested PCR and the COBAS AMPLICOR test, evaluated by using 10-fold dilutions of purified full-length CMV Towne DNA, showed a lower detection limit of 100 copies/ml for the nested PCR and 1,000 copies/ml for the COBAS AMPLICOR PCR. By the nested PCR, the COBAS AMPLICOR PCR, and NASBA, the diagnostic sensitivities were 93.3, 86.6, and 93.3%, respectively, and the specificities were 93.7, 93.7, and 87.5%, respectively. In five patients discordant CSF and histopathology results were found by one or more of the assays (Table 1, patients 14 and 15; Table 2, patients 16 to 18). By the nested PCR, the results of the retrospective and prospective analyses were identical, showing interassay reproducibilities of 100%.

TABLE 1.

Histopathological and CSF findings for 15 patients with CMV-E

Patient no. CMV ventriculo-encephalitisa CMV parenchymal lesions (localization) CMV infected cell scoreb Other CNS findingsc Other CMV localizationsc Anti-CMV treatment ongoing at the time of CSF samplingd Interval from CSF sampling to death (days) Result by nested CMV PCR of CSF No. of CMV copies/ml of CSF by COBAS AMPLICOR PCR Result by NucliSens CMV pp67 NASBA of CSF
1 Diffuse Multiple (brain, cerebellum, brain stem) +++ None Lung, adrenal glands None 58 Positive >100,000 Positive
2 Diffuse None +++ HSV-1e encephalitis Retina None 20 Positive >100,000 Positive
3 Diffuse Single (brain) ++ HSV-2f encephalitis None None 47 Positive >100,000 Positive
4 Diffuse Multiple (brain, cerebellum, brain stem) ++ Non-Hodgkin's lymphoma None Ganciclovir 93 Positive >100,000 Positive
5 Diffuse Multiple (brain, cerebellum, brain stem) +++ None Adrenal glands, retina None 37 Positive 99,800 Positive
6 Diffuse None ++ None Adrenal glands None 150 Positive 70,300 Positive
7 Diffuse Multiple (brain stem) +++ None Retina Ganciclovir 4 Positive 60,900 Positive
8 Diffuse Multiple (brain, cerebellum, brain stem) +++ None Lung, adrenal glands, retina Foscamet 3 Positive 47,800 Positive
9 Diffuse Multiple (brain) ++ HIV encephalitis Retina Ganciclovir 42 Positive 44,900 Positive
10 Diffuse Multiple (brain, cerebellum) + HSV-1 encephalitis Adrenal glands, retina Ganciclovir 29 Positive 15,100 Positive
11 Diffuse None +++ None None Ganciclovir 12 Positive 11,900 Positive
12 Diffuse Multiple (brain, cerebellum, brain stem) ++ None Lung, adrenal glands Foscamet 178 Positive 6,400 Positive
13 Focal None + Toxoplasmosis None None 8 Positive 1,900 Positive
14 Focal Single (brain) +++ None Adrenal glands, retina Ganciclovir 17 Positive <400 Positive
15 Focal Multiple (brain) ++ Mycobacterium tuberculosis meningoencephalitis Lungs, brain, adrenal glands, esophagus None 21 Negative <400 Negative
a

Diffuse ventriculoencephalitis, present throughout the periventricular lining of a tissue section; focal ventriculoencephalitis, only small foci with aggregates of CMV-infected cells. 

b

+, 1 to 5 infected cells per 10 high-power fields; ++, 6 to 20 infected cells per 10 HPF high-power fields; +++, >20 infected cells per 10 high-power fields. 

c

At postmortem examination. The retina was not examined at autopsy, and retinitis was diagnosed in vivo by ophthalmological examination. 

d

Anti-CMV drugs were administered between the time of CSF sampling and death for all but one patient (patient 15) (median time, 42 days). 

e

HSV-1, herpes simplex virus type 1. 

f

HSV-2, herpes simplex virus type 2. 

TABLE 2.

Histopathological and CSF findings for 16 patients without CMV infection of CNSa

Patient no. Other CNS findingsa Other CMV localizationsa Anti-CMV treatment ongoing at the time of CSF samplingb Interval from CSF sampling to death (days) Results by nested CMV PCR of CSF No. of CMV DNA copies of CSF by COBAS AMPLICOR PCR Result by NucliSens CMV pp67 NASBA of CSF
16 Nonspecific subependymal gllosis Adrenal glands, colon, lungs None 42 Positive 3,500 Negative
17 HIV encephalitis Adrenal glands None 5 Negative <400 Positive
18 Cryptococcus neoformans meningoencephalitis Adrenal glands None 52 Negative <400 Positive
19 Ischemic lesions None Ganciclovir 59 Negative <400 Negative
20 Aspergillosis Adrenal glands Foscarnet, ganciclovir 36 Negative <400 Negative
21 No lesions Lung, adrenal glands, retina Ganciclovir 28 Negative <400 Negative
22 Unspecific myelitis None None 8 Negative <400 Negative
23 HIV encephalitis Retina Ganciclovir 28 Negative <400 Negative
24 No lesions None None 25 Negative <400 Negative
25 Toxoplasmosis None None 46 Negative <400 Negative
26 Crytococcus neoformans meningoencephalitis Adrenal glands None 19 Negative <400 Negative
27 Edema None None 12 Negative <400 Negative
28 No lesions None None 77 Negative <400 Negative
29 Toxoplasmosis Lung None 38 Negative <400 Negative
30 Non-Hodgkin's lymphoma Lung, stomach, heart None 43 Negative <400 Negative
31 Non-Hodgkin's lymphoma None None 11 Negative <400 Negative
a

At postmortem examination. The retina was not examined at autopsy, and retinitis was diagnosed in vivo by ophthalmological examination. 

b

Anti-CMV drugs were administered between the time of CSF sampling and death for five patients (patients 16, 19 to 21, and 23) (median, 32 days). 

By the COBAS AMPLICOR PCR, the median CMV DNA load was 65,600 copies/ml (range, 6,400 to 100,000 copies/ml) for 12 patients with diffuse ventriculoencephalitis and <400 copies/ml (range, <400 to 1,900 copies/ml) for three patients with a focal form (P < 0.01 by the Mann-Whitney test). No significantly different distributions of the CMV DNA loads were observed according to the presence of associated parenchymal lesions, CMV-infected cell score, extracerebral CMV localization, other CNS diseases, or ongoing anti-CMV therapy, although untreated patients tended to have higher viral loads (Table 1).

The results obtained in this study by all three techniques closely correlated with the postmortem diagnoses and showed similar diagnostic sensitivity and specificity values. These values were similar to those obtained for two other patient series in which CSF findings were compared with the histopathological diagnoses (4, 5). Overall, the analytical sensitivities of the assays therefore appeared to be adequate to specifically distinguish patients with CMV-E. Furthermore, the results of the present retrospective evaluation by nested PCR were identical to those prospectively obtained by the same assay at the time of patient evaluation 2 to 8 years earlier, which had allowed a premortem diagnosis for the majority of patients. This indicates the high interassay reproducibility of this technique and the good rate of recovery of amplifiable genomes after longterm storage at −80°C.

The COBAS AMPLICOR PCR is a quantitative assay developed to measure CMV levels in plasma or peripheral blood leukocytes (13, 14). To our knowledge, only Roche's other commercially available PCR assay, the qualitative plasma AMPLICOR CMV test, but not the COBAS AMPLICOR PCR assay, has been described for analysis of CSF (11, 15). In the present study, in which we compared the findings obtained with CSF with the neuropathological findings, we found that the analytical and diagnostic sensitivities of the COBAS AMPLICOR PCR were only slightly lower than those of the nested PCR and NASBA, and the COBAS AMPLICOR test failed to recognize only one patient with focal ventriculoencephalitis. The threshold of 400 copies/ml, calculated as representing the best compromise between sensitivity and specificity in identifying HIV-infected patients at risk for the development of systemic CMV disease (12), therefore also seems to be useful for the identification of patients with CMV-E. Furthermore, by the COBAS AMPLICOR assay we found a significant association between high CSF CMV DNA levels and the presence of diffuse rather than focal periventricular lesions and found that the presence of focal parenchymal lesions did not seem to affect the viral load in CSF significantly. These findings are consistent with the hypothesis that the high CSF CMV DNA burden in patients with ventriculoencephalitis is probably due to the direct release of virus from the adjacent infected ependymal and subependymal tissues. From a practical point of view, the ability to discriminate extended from milder lesions may be important for prognostic considerations.

Whereas the nested PCR and the COBAS AMPLICOR PCR detect viral DNA, the NASBA detects late CMV transcripts. A recent evaluation of the NucliSens CMV pp67 NASBA with CSF from HIV-infected patients with a clinical diagnosis of CMV-associated or other opportunistic CNS diseases showed that the test was highly specific but less sensitive than PCR of DNA for the diagnosis of CMV-related neurological complications (17). The results of the present study, specifically designed to compare the results obtained with CSF with those obtained by histopathological examination, not only confirm the high degree of specificity of the NASBA but also show that its sensitivity is not less than that of the PCR assays with DNA.

Discordance between the findings obtained with CSF and postmortem findings were obtained for five patients. Positive PCR results in the absence of brain lesions caused by CMV can be explained by the possible effects of anti-CMV drugs administered between the time of sampling and death, by the inevitable limitations of neuropathological analysis to sample all the microscopic lesions, or by the possible presence of active CMV replication in the brain or CSF in the absence of established lesions. The detection in CSF of viral DNA originating from the blood might be another explanation for these discordant findings. However, previous reports indicated that CMV DNA is generally recovered in the CNS irrespective of CMV DNA detection in blood or of an extracerebral CMV involvement (4, 5, 10). We constantly used strict laboratory procedures to avoid contamination, and so the presence of exogenous nucleic acids in these CSF-positive samples with discordant results was unlikely. The time that elapsed between CSF sampling and postmortem diagnosis may have resulted in a negative CSF result in the presence of CMV-E. On the other hand, the presence of amplification inhibitors in the clinical specimens was unlikely because both of the commercial assays include amplification controls and no inhibition was ever observed.

In conclusion, the two commercial assays examined in the present study are useful additional tools for the diagnosis of CMV-E in HIV-infected patients. Furthermore, the COBAS AMPLICOR assay enables quantification of DNA in CSF, which not only is important for diagnostic and prognostic factors but might also provide precious information for monitoring of antiviral treatment (7). Although the prevalence of CMV-E in HIV-infected patients has decreased since the introduction of highly active antiretroviral therapy, we believe that monitoring of CMV infection of the CNS is still important because a number of patients cannot tolerate or fail to respond to these regimens. Furthermore, although not evaluated in the present study, these new tests might prove to be useful for the diagnosis of other CMV-associated neurological diseases, such as those observed in transplant recipients, neonates with congenital CMV infection, or immunocompetent patients (1).

Acknowledgments

This study was supported by the Third AIDS Program (grant 50B.8) of the Istituto Superiore di Sanità, Rome, Italy.

We thank Organon Teknika and Roche Diagnostics for kindly supplying the reagents.

REFERENCES

  • 1.Arribas J R, Storch G A, Clifford D B, Tselis A C. Cytomegalovirus encephalitis. Ann Intern Med. 1996;125:577–587. doi: 10.7326/0003-4819-125-7-199610010-00008. [DOI] [PubMed] [Google Scholar]
  • 2.Blank B S, Meenhorst P L, Mulder J W, Weverling G J, Putter H, Pauw W, van Dijk W C, Smits P, Lie-A-Ling S, Reiss P, Lange J M. Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol. 2000;38:563–569. doi: 10.1128/jcm.38.2.563-569.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Blok M J, Goossens V J, Vanherle S J, Top B, Tacken N, Middeldorp J M, Christiaans M H, van Hooff J P, Bruggeman C A. Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipients by nucleic acid sequence-based amplification. J Clin Microbiol. 1998;36:1341–1346. doi: 10.1128/jcm.36.5.1341-1346.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cinque P, Vago L, Brytting M, Castagna A, Accordini A, Sunqvist V-A, Zanchetta N, D'Arminio Monforte A, Wahren B, Lazzarin A, Linde A. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis. 1992;166:1408–1411. doi: 10.1093/infdis/166.6.1408. [DOI] [PubMed] [Google Scholar]
  • 5.Cinque P, Vago L, Dahl H, Brytting M, Terreni M R, Fornara C, Racca S, Castagna A, D'Arminio Monforte A, Wahren B, Lazzarin A, Linde A. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS. 1996;10:951–958. doi: 10.1097/00002030-199610090-00004. [DOI] [PubMed] [Google Scholar]
  • 6.Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS. 1997;11:1–17. doi: 10.1097/00002030-199701000-00003. [DOI] [PubMed] [Google Scholar]
  • 7.Cinque P, Cleator G M, Weber T, Monteyne P, Sindic C, Gerna G, Van Loon A, Klapper P E for the European Union Concerted Action on Virus Meningitis and Encephalitis. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. J Neurovirol. 1998;4:120–132. doi: 10.3109/13550289809113490. [DOI] [PubMed] [Google Scholar]
  • 8.Clifford D B, Buller R S, Mohammed S, Robinson L, Storch G A. Use of polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. Neurology. 1993;43:75–79. doi: 10.1212/wnl.43.1_part_1.75. [DOI] [PubMed] [Google Scholar]
  • 9.Fox J D, Brink N S, Zuckerman M A, Neild P, Gazzard B G, Tedder R S, Miller R F. Detection of herpesvirus DNA by “nested” PCR in CSF of HIV-infected persons with neurological disease: a prospective evaluation. J Infect Dis. 1995;172:1087–1090. doi: 10.1093/infdis/172.4.1087. [DOI] [PubMed] [Google Scholar]
  • 10.Gozlan J, Salord J M, Roullet E, Baudrimont M, Caburet F, Picard O, Meyoas M C, Duvivier C, Jacomet C, Petit J C. Rapid detection of cytomegalovirus DNA in cerebrospinal fluid of AIDS patients with neurologic disorders. J Infect Dis. 1992;166:1416–1421. doi: 10.1093/infdis/166.6.1416. [DOI] [PubMed] [Google Scholar]
  • 11.Long C M, Drew L, Miner R, Jekie-McMullen D, Impraim C, Kao S Y. Detection of cytomegalovirus in plasma and cerebrospinal fluid specimens from human immunodeficiency virus-infected patients by the AMPLICOR CMV test. J Clin Microbiol. 1998;36:2434–2438. doi: 10.1128/jcm.36.9.2434-2438.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pellegrin I, Garrigue I, Binquet C, Chene G, Neau D, Bonot P, Bonnet F, Fleury H, Pellegrin J L. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol. 1999;37:3124–3132. doi: 10.1128/jcm.37.10.3124-3132.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sia I G, Wilson J A, Espy M J, Paya C V, Smith T F. Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation. J Clin Microbiol. 2000;38:600–606. doi: 10.1128/jcm.38.2.600-606.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tong C Y, Cuevas L E, Williams H, Bakran A. Comparison of two commercial methods for measurement of cytomegalovirus load in blood samples after renal transplantation. J Clin Microbiol. 2000;38:1209–1213. doi: 10.1128/jcm.38.3.1209-1213.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Weinberg A, Spiers D, Cai G-Y, Long C M, Sun R, Tevere V. Evaluation of a commercial PCR kit for diagnosis of cytomegalovirus infection of the central nervous system. J Clin Microbiol. 1998;36:3382–3384. doi: 10.1128/jcm.36.11.3382-3384.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wolf D G, Spector S A. Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis. 1992;166:1412–1415. doi: 10.1093/infdis/166.6.1412. [DOI] [PubMed] [Google Scholar]
  • 17.Zhang F, Tetali S, Wang X P, Kaplan M H, Cromme F V, Ginocchio C C. Detection of human cytomegalovirus pp67 late gene transcripts in cerebrospinal fluid of human immunodeficiency virus type 1-infected patients by nucleic acid sequence-based amplification. J Clin Microbiol. 2000;38:1920–1925. doi: 10.1128/jcm.38.5.1920-1925.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES